The standard busulfan-cyclophosphamide myeloablative conditioning regimen is associated with substantial non-relapse mortality in patients older than 40 years with acute myeloid leukaemia who are undergoing allogeneic stem-cell transplantation. Because the combination of busulfan plus fludarabine has been proposed to reduce non-relapse mortality, we aimed to compare this treatment with busulfan plus cyclophosphamide as a preparative regimen in these patients.
Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial / A. Rambaldi, A. Grassi, A. Masciulli, C. Boschini, M.C. Micò, A. Busca, B. Bruno, I. Cavattoni, S. Santarone, R. Raimondi, M. Montanari, G. Milone, P. Chiusolo, D. Pastore, S. Guidi, F. Patriarca, A.M. Risitano, G. Saporiti, M. Pini, E. Terruzzi, W. Arcese, G. Marotta, A.M. Carella, A. Nagler, D. Russo, P. Corradini, E.P. Alessandrino, G.F. Torelli, R. Scimè, N. Mordini, E. Oldani, R.M. Marfisi, A. Bacigalupo, A. Bosi. - In: THE LANCET ONCOLOGY. - ISSN 1470-2045. - 16:15(2015 Nov), pp. 1525-1536. [10.1016/S1470-2045(15)00200-4]
Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial
A. RambaldiPrimo
;G. Saporiti;P. Corradini;
2015
Abstract
The standard busulfan-cyclophosphamide myeloablative conditioning regimen is associated with substantial non-relapse mortality in patients older than 40 years with acute myeloid leukaemia who are undergoing allogeneic stem-cell transplantation. Because the combination of busulfan plus fludarabine has been proposed to reduce non-relapse mortality, we aimed to compare this treatment with busulfan plus cyclophosphamide as a preparative regimen in these patients.
| File | Dimensione | Formato | |
|---|---|---|---|
|
TheLancet_Busulfan_2015.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
458.53 kB
Formato
Adobe PDF
|
458.53 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
|
r2.pdf
accesso aperto
Tipologia:
Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione
1.79 MB
Formato
Adobe PDF
|
1.79 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
